CN104529893B - 一类可以作为高尔基体细胞器探针的喹啉染料 - Google Patents
一类可以作为高尔基体细胞器探针的喹啉染料 Download PDFInfo
- Publication number
- CN104529893B CN104529893B CN201410840037.5A CN201410840037A CN104529893B CN 104529893 B CN104529893 B CN 104529893B CN 201410840037 A CN201410840037 A CN 201410840037A CN 104529893 B CN104529893 B CN 104529893B
- Authority
- CN
- China
- Prior art keywords
- cell device
- golgi
- compound
- quinoline
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract description 46
- 210000003652 golgi cell Anatomy 0.000 title abstract description 28
- 239000000523 sample Substances 0.000 title abstract description 13
- 238000003384 imaging method Methods 0.000 claims abstract description 11
- 238000002372 labelling Methods 0.000 claims abstract description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 12
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 150000004982 aromatic amines Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 7
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical group NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000010189 synthetic method Methods 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 20
- 239000000975 dye Substances 0.000 abstract description 18
- 230000003834 intracellular effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 3
- 201000008968 osteosarcoma Diseases 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229940106189 ceramide Drugs 0.000 description 9
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 9
- 230000005284 excitation Effects 0.000 description 9
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003248 quinolines Chemical class 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 210000001520 comb Anatomy 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- -1 pyropheophorbide α methyl ester Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 0 *C(CC(C(F)(F)F)=O)=O Chemical compound *C(CC(C(F)(F)F)=O)=O 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- QAMFBRUWYYMMGJ-UHFFFAOYSA-N hexafluoroacetylacetone Chemical compound FC(F)(F)C(=O)CC(=O)C(F)(F)F QAMFBRUWYYMMGJ-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 101000799388 Homo sapiens Thiopurine S-methyltransferase Proteins 0.000 description 1
- 102100034162 Thiopurine S-methyltransferase Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- RNRGYNNIISFTDF-IFEZDQECSA-N [(2r,3r,3ar,6ar)-3-[1-[(1r,3as,7as)-4,4,7a-trimethyl-2,3,3a,5,6,7-hexahydro-1h-inden-1-yl]ethenyl]-5-oxo-3,3a,4,6a-tetrahydro-2h-furo[2,3-b]furan-2-yl] acetate Chemical compound C1C[C@@H](C(CCC2)(C)C)[C@@]2(C)[C@H]1C(=C)[C@H]1[C@H]2CC(=O)O[C@H]2O[C@@H]1OC(=O)C RNRGYNNIISFTDF-IFEZDQECSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- RNRGYNNIISFTDF-UHFFFAOYSA-N norrisolide Natural products C1CC(C(CCC2)(C)C)C2(C)C1C(=C)C1C2CC(=O)OC2OC1OC(=O)C RNRGYNNIISFTDF-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- TVIVIEFSHFOWTE-UHFFFAOYSA-K tri(quinolin-8-yloxy)alumane Chemical compound [Al+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 TVIVIEFSHFOWTE-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明涉及一类可以作为高尔基体细胞器探针的新型喹啉染料,通过对该染料与商用的高尔基体细胞器染料在人骨肉瘤细胞U2OS细胞内成像结果的比对,证实了该染料对高尔基体细胞器的靶向定位。该染料在标记高尔基体细胞器领域有着巨大的潜在作用。
Description
技术领域
本发明属于材料领域,具体涉及一类可以作为高尔基体细胞器探针的新型喹啉染料、其制备方法和用途。
背景技术
喹啉类化合物作为制药工程中很多药物分子的中间体,是有机化学中最重要的领域之一。天然的喹啉衍生物奎宁是第一个有效治疗疟疾的药物分子,很多喹啉衍生物(例如氯喹,甲氟喹)具有抗疟疾活性。事实上,奎宁也是历史上有记录的荧光分子之一,具有很亮的蓝光发射,时至今日依然被用在荧光量子产率测定领域中。另外,8-羟基喹啉铝亦是第一个用在有机发光二极管(OLED)的化合物(C.W.Tang and S.A.VanSlyke,Appl.Phys.Lett.,1987,51,913)。鉴于喹啉类化合物有着如此重要的作用,近年来仍有大量对喹啉类化合物的研究,特别是在荧光传感方面。例如,有很多基于喹啉衍生物的荧光探针被用来检测与生物相关的物质,如质子(G.Li,D.Zhu,L.Xue,H.Jiang,Org.Lett.,2013,15,5020-5023.),Cd2+(Q.Zhao,R.-F.Li,S.-K.Xing,X.-M.Liu,T.-L.Hu,X.-H.Bu,Inorg.Chem.,2011,50,10041-10046.),Zn2+(X.Meng,S.Wang,Y.Li,M.Zhu,Q.Guo,Chem.Commun.,2012,48,4196-4198.),Hg2+(B.N.Ahamed,P.Ghosh,Dalton Trans.,2011,40,12540-12547.),Al3+(D.Maity,T.Govindaraju,Chem.Commun.,2012,48,1039-1041.),氰化物(V.Zlojutro,Y.Sun,Z.M.Hudson,S.Wang,Chem.Commun.,2011,47,3837-3839.),氟化物(P.G.Sutariya,A.Pandya,A.Lodha,S.K.Menon,Analyst,2013,138,2531-2535.),焦磷酸盐(Y.Mikata,A.Ugai,R.Ohnishi,H.Konno,Inorg.Chem.,2013,52,10223-10225)及碳水化合物(W.Yang,J.Yan,G.Springsteen,S.Deeter,B.Wang,Bioorg.Med.Chem.Lett.,2003,13,1019-1022.)等。
高尔基体细胞器作为细胞分泌物最后的加工和包装场所,有着极其重要的地位,使用探针对高尔基体细胞器准确标记有助于进一步探究高尔基体细胞器的工作机制。现有的已经商业化的高尔基体细胞器探针主要是美国生命技术公司(Life technologies)生产的FL C5Ceramide,TR Ceramide和Alexa Fluor594-conjugatedWGAlectin,以及List Biological Labs生产的TRITC–CTB(TRITC-labeledcholera toxin B subunit),但是这些探针结构复杂,成本颇高。
亦有文献报道一些能够定位在高尔基体细胞器的染料。X.Sun等(Photochemistryand Photobiology,2002,75(6):644–651)探究了焦脱镁叶绿酸α甲酯在光动力治疗人类肺癌细胞中的突出作用,并指出其分布在高尔基体细胞器。但是焦脱镁叶绿酸α甲酯并不是只存在高尔基体细胞器上,它分布在细胞内的膜系统,包括内质网,线粒体,溶酶体和高尔基体,所以并不能特异定位高尔基体。Masaaki Sawa等(PNAS,2006,103(33):12371–12376)合成了一类通过点击化学反应活化荧光探针的方法来研究细胞内岩藻糖基化过程,可以特异定位到高尔基体细胞器,但是细胞必须预先进行特定的处理,才能定位出高尔基体细胞器。Gianni Guizzunti等(Bioorganic&Medicinal Chemistry Letters,2007,17:320–325)合成了一系列基于norrisolide的功能化探针来研究高尔基体囊泡形成的过程,这些功能探针有的可以诱发高尔基体发生大规模且不可逆的分裂。但是这些功能化的探针合成步骤繁多,不够简便。因此,如何能够以低成本快速简便且特异地标记高尔基体细胞器值得进一步探究。
发明内容
在本发明中,我们合成了一类可以作为高尔基体细胞器探针的新型喹啉染料,可以低成本,高效率,高特异性地快速标记高尔基体细胞器。
我们依据Combs喹啉合成方法,采用芳胺和β-二酮反应合成目标产物。但是传统的Combs喹啉合成方法反应条件苛刻,需要在高温强酸的催化下反应。为了提高反应活性且更好地使用在细胞内,我们对两种反应物的结构进行了一定的设计,在β-二酮上引入了强吸电基-CF3,芳胺采用两个氨基取代的芳胺。这样反应在极其温和的条件下(在CHCl3中温度只需80℃,且不需要任何催化剂)便可获得较高的产率。两种反应物的具体结构如下:
同时为了更好地了解这两种喹啉染料的荧光性质以便对接下来的细胞实验有所指导,我们测定了这两种喹啉染料在八种不同极性溶剂(分别是正己烷,甲苯,四氢呋喃,乙酸乙酯,氯仿,二氯甲烷,丙酮和甲醇)中的紫外吸收谱和荧光发射谱。
在进行细胞实验时,我们选择了一种商用的高尔基体细胞器染料TRCeramide和我们所设计的两种喹啉染料作为对比,使用常用的人骨肉瘤细胞U2OS细胞作为实验对象。经过30min的细胞胞吞后,在共聚焦显微镜下分别使用单光子和双光子激光器对两种染料的细胞成像进行了观察,发现我们所设计的喹啉染料对高尔基体细胞器有着很好的定位,基本能与商用的TR Ceramide在高尔基体细胞器上的分布完全重叠。
因此,本发明的第一个方面提供式(I)的化合物
其中,R为取代的苯基或萘基,所述取代的苯基或萘基的取代基选自氢、卤素、C1-C6烷基、-OCH3、-OH、-NH2或-CN。
在优选的实施方案中,所述化合物为
分别命名为Quinoline1和Quinoline2。
本发明的第二个方面提供式(I)的化合物的合成方法,所述方法包括将芳胺与β-二酮在溶剂中反应的步骤,其中所述芳胺为两个氨基取代的芳胺,所述β-二酮上带有强吸电基。
在优选的实施方案中,所述强吸电基为三氟甲基。
在优选的实施方案中,所述反应不需要催化剂。
在优选的实施方案中,所述溶剂为有机溶剂或水,所述有机溶剂优选为氯仿,反应温度范围从室温到溶剂沸点,优选为80℃。
在优选的实施方案中,所述β-二酮为4,4,4-三氟-1-苯基-1,3-丁二酮或4,4,4-三氟-1-(2-萘基)-1,3-丁二酮。
在优选的实施方案中,所述芳胺为间苯二胺。
本发明的第三个方面提供本发明第一个方面所述的化合物作为细胞染料的用途。
本发明的第四个方面提供本发明第一个方面所述的化合物用于标记高尔基体以及成像高尔基体的用途。
本发明具有以下优点:
1.合成简单,仅需要一步合成即可得到较高产率的目标产物;
2.反应条件温和,即使在水中也能进行反应。成本低廉,1g造价不足100元。且能
3.快速(30min)特异地定位在高尔基体细胞器上。
因此与传统高尔基体细胞器探针相比,我们成功实现了低成本,高效率,高特异性地快速标记高尔基体细胞器,该染料在标记高尔基体细胞器领域有着巨大的潜在作用。
附图说明
图1 Quinoline 1在不同极性溶剂中的紫外吸收谱
图2 Quinoline 1在不同极性溶剂中的荧光发射谱
图3 Quinoline 2在不同极性溶剂中的紫外吸收谱
图4 Quinoline 2在不同极性溶剂中的荧光发射谱
图5 Quinoline 1在不同极性溶剂中的荧光图片(365nm激发)
从左到右的溶剂分别为:正己烷,甲苯,二氯甲烷,氯仿,四氢呋喃,乙酸乙酯,丙酮,甲醇
图6 Quinoline 2在不同极性溶剂中的荧光图片(365nm激发)
从左到右的溶剂分别为:正己烷,甲苯,二氯甲烷,氯仿,四氢呋喃,乙酸乙酯,丙酮,甲醇
图7 Quinoline2(a)和TR Ceramide(b)在U2OS细胞内的成像以及两者的重叠(c),单光子激发(Quinoline2激发波长488nm,发射波长范围:489-580nm,TR Ceramide激发波长633nm,发射波长范围:634-740nm)
图8 Quinoline 1(a)和TR Ceramide(b)在U2OS细胞内的成像以及两者的重叠(c),双光子激发(激发波长790nm)
图9 Quinoline 2(a)和TR Ceramide(b)在U2OS细胞内的成像以及两者的重叠(c),双光子激发(激发波长790nm)
图10在超纯水中合成的Quinoline1(a:日光下,b:紫外光下,激发波长365nm)
图11在超纯水中合成的Quinoline3(a:日光下,b:紫外光下,激发波长365nm)
具体实施方式
以下实施例将对本发明作进一步说明,以便更好的理解及使用本发明。本发明中的β-二酮购自TCI(上海),六氟乙酰丙酮购自Energy Chemical,其余试剂均购自AladdinReagent(上海)。
实施例1
在氯仿中合成两种喹啉染料:
Quinoline1的合成步骤:
将1.00g(4.63mmol)4,4,4-三氟-1-苯基-1,3-丁二酮溶于50ml的氯仿中,向其中加入0.50g(4.63mmol)的间苯二胺。将反应体系浸在油浴中,在N2保护下,80℃回流搅拌约10小时。随后减压旋转蒸发除去有机溶剂,将得到的粗产物在氯仿中重结晶,并用正己烷洗涤晶体,真空干燥得到浅草绿色针状晶体Quinoline1(1.17g,88%)。Quinoline1的结构表征:1H NMR(300MHz,CDCl3)δ8.14(m,2H,4-2’-ArH),7.93(m,1H,5-H),7.89(s,1H,3-H),7.52(m,3H,4-3’,4’,5’-ArH),7.39(d,J=2.2Hz,1H,8-H),7.09(dd,J=9.0,2.4Hz,1H,6-H),4.22(broad s,7-NH2,2H).MS(HRMS):m/z calcd forC16H12F3N2 +289.09526,found289.09399。
Quinoline2的合成步骤:
将1.00g(3.76mmol)4,4,4-三氟-1-(2-萘基)-1,3-丁二酮溶于50ml的氯仿中,向其中加入0.41g(3.76mmol)的间苯二胺。将反应体系浸在油浴中,在N2保护下,80℃回流搅拌约10小时。随后减压旋转蒸发除去有机溶剂,将得到的粗产物在氯仿中重结晶,并用正己烷洗涤晶体,真空干燥得到黄色纤维状晶体Quinoline2(1.14g,90%)。Quinoline2的结构表征:1H NMR(300MHz,CDCl3)δ8.60(s,1H,4-2’-ArH),8.34(d,J=8.6Hz,1H,5-H),8.04(s,1H,3-H),7.94(m,4H,4-5’,6’,7’,8’-ArH),7.55(dd,J=6.2,3.2Hz,2H,4-3’,4’H),7.43(d,J=2.3Hz,1H,6-H),7.09(dd,J=9.0,2.4Hz,1H,8-H),4.22(broad s,7-NH2,2H).MS(HRMS):m/z calcd for C20H14F3N2 +339.11091,found 339.10999。
Quinoline 1和Quinoline2的紫外吸收谱和荧光发射谱以及荧光图片如图1-6所示,根据这些图,可以看出紫外最大吸收在近紫外至蓝光区域,且随着溶剂极性增加,紫外最大吸收峰和荧光最大发射峰都向长波长处移动,显示了很强的分子内系间穿越性质。
应用例1
细胞实验:在37℃下,气氛为5%CO2的培养箱(Thermo Fisher Scientific Inc)里培养U2OS细胞(购自ATCC)。待细胞在盖玻片上的分布达到80-90%时,取出,用磷酸缓冲液(GIBCO/Life Technologies)洗去培养基。将分别溶有喹啉染料(2ug/ml)以及商用TR Ceramide(Life Technologies)(1umol)的两份培养液(无血清)同时加到培养基(GIBCO/Life Technologies)中。30分钟后,用磷酸缓冲液洗去多余的培养基,并用封片剂(Sigma aldrich公司)对细胞进行固定封片。将固定了的细胞置于蔡司共聚焦显微镜系统(Zeiss LSM 710)下观察,单光子细胞成像使用了氩离子激光器(ZeissLASOSlaser)(λex=488nm,25mW),双光子细胞成像使用了飞秒锁模的钛蓝宝石激光器(Coherent,Inc)(λex=790nm,3.5W)。使用40x的油镜(EC Plan-Neofluar,NA 1.30)观察细胞成像情况,每个荧光信号都用Zeiss TPMT检测器捕捉。经过30min的细胞胞吞后,在共聚焦显微镜下分别使用单光子(图7)和双光子激光器(图8和9)对两种染料的细胞成像进行了观察,发现我们所设计的喹啉染料对高尔基体细胞器有着很好的定位,基本能与商用的TR Ceramide在高尔基体细胞器上的分布完全重叠。
实施例2
在水中进行Combs喹啉合成方法:
水相比其他有机溶剂,是无毒无害的绿色溶剂,而且本发明中的反应本是脱水反应,却能在水中反应,证明本发明的反应高效。
Quinoline1的合成步骤:
将0.25g(1.16mmol)4,4,4-三氟-1-苯基-1,3-丁二酮和0.12g(1.16mmol)间苯二胺加到20ml的超纯水中。无需搅拌和加热,置于室温下4天后,即有浅黄绿色针状产物悬浮在水中,如图10。
Quinoline3的合成步骤:
将0.25g(1.20mmol)六氟乙酰丙酮和0.13g(1.20mmol)间苯二胺加到20ml的超纯水中。无需搅拌和加热,置于室温2天后,即有黄色纤维状产物悬浮在水中,如图11。Quinoline 3的结构表征:1H NMR(300MHz,CDCl3)δ8.00(dd,J=9.1,1.7Hz,1H,5-H),7.71(s,1H,3-H),7.38(d,J=1.8Hz,1H,8-H),7.22(dd,J=9.1,1.9Hz,1H,6-H),4.08(broad s,7-NH2,2H).MS(HRMS):m/z calcd for C11H7F6N2 +281.05134,found 281.05035。
Claims (9)
1.式(I)的化合物
其中,R为苯基或萘基。
2.一种式(I)的化合物的合成方法,
其中,R为苯基或萘基,
所述方法包括将芳胺与β-二酮在溶剂中反应的步骤,其中所述芳胺为间苯二胺,所述β-二酮为4,4,4-三氟-1-苯基-1,3-丁二酮或4,4,4-三氟-1-(2-萘基)-1,3-丁二酮。
3.根据权利要求2所述的方法,所述反应不需要催化剂。
4.根据权利要求2所述的方法,所述溶剂为有机溶剂或水,反应温度范围为室温至溶剂的沸点。
5.根据权利要求4所述的方法,所述有机溶剂为氯仿。
6.根据权利要求4所述的方法,所述反应温度为80℃。
7.根据权利要求1所述的化合物,所述化合物选自
分别命名为Quinoline1和Quinoline2。
8.权利要求1或7所述的化合物作为细胞染料的用途。
9.权利要求1或7所述的化合物用于标记高尔基体以及成像高尔基体的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410840037.5A CN104529893B (zh) | 2014-12-30 | 2014-12-30 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410840037.5A CN104529893B (zh) | 2014-12-30 | 2014-12-30 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104529893A CN104529893A (zh) | 2015-04-22 |
CN104529893B true CN104529893B (zh) | 2016-08-24 |
Family
ID=52845573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410840037.5A Expired - Fee Related CN104529893B (zh) | 2014-12-30 | 2014-12-30 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104529893B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109280017A (zh) * | 2018-08-30 | 2019-01-29 | 河南师范大学 | 一种双光子荧光高尔基体定位剂及其制备方法和应用 |
JP7217460B2 (ja) * | 2019-05-13 | 2023-02-03 | 学校法人昭和薬科大学 | 新規化合物及び該化合物を含む脂肪滴検出用試薬 |
CN110878049B (zh) * | 2019-12-16 | 2022-02-25 | 济南大学 | 一种特异性分析高尔基体中硫化氢的荧光探针制备与应用 |
CN111039866B (zh) * | 2019-12-16 | 2022-02-25 | 济南大学 | 一种靶向高尔基体的硫化氢荧光探针、制备方法与应用 |
CN111995573B (zh) * | 2020-09-04 | 2022-10-11 | 济南大学 | 一种高灵敏的亚硝酸盐比色荧光探针、制备方法与应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1745179A (zh) * | 2003-01-02 | 2006-03-08 | 拜澳富斯毫微科学有限公司 | 在小样品体积中分子分析的方法和装置 |
US20100178251A1 (en) * | 2006-08-11 | 2010-07-15 | The University Of Medicine And Dentistry Of New Jersey | Dual-Sensitizer-Containing Luminescent Compounds, Conjugates, and Uses Thereof |
US20110263861A1 (en) * | 2009-11-19 | 2011-10-27 | Kyushu University, National University Corporation | Quinoline compound |
CN102680446A (zh) * | 2012-05-25 | 2012-09-19 | 中国人民解放军第三军医大学 | 检测白藜芦醇在靶细胞定位的方法 |
CN103957910A (zh) * | 2011-10-21 | 2014-07-30 | 葛兰素史克有限责任公司 | 增加先天免疫反应的化合物和方法 |
-
2014
- 2014-12-30 CN CN201410840037.5A patent/CN104529893B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1745179A (zh) * | 2003-01-02 | 2006-03-08 | 拜澳富斯毫微科学有限公司 | 在小样品体积中分子分析的方法和装置 |
US20100178251A1 (en) * | 2006-08-11 | 2010-07-15 | The University Of Medicine And Dentistry Of New Jersey | Dual-Sensitizer-Containing Luminescent Compounds, Conjugates, and Uses Thereof |
US20110263861A1 (en) * | 2009-11-19 | 2011-10-27 | Kyushu University, National University Corporation | Quinoline compound |
CN103957910A (zh) * | 2011-10-21 | 2014-07-30 | 葛兰素史克有限责任公司 | 增加先天免疫反应的化合物和方法 |
CN102680446A (zh) * | 2012-05-25 | 2012-09-19 | 中国人民解放军第三军医大学 | 检测白藜芦醇在靶细胞定位的方法 |
Non-Patent Citations (6)
Title |
---|
High concentration of calcium ions in Golgi apparatus;XUE SHAOBAI,等;《Cell Research》;19940630;第4卷(第01期);第97-108页 * |
Photodynamic Therapy with Pyropheophorbide-a Methyl Ester in Human Lung Carcinoma Cancer Cell: Efficacy, Localization and Apoptosis;X.Sun,等;《Photochemistry and Photobiology》;20070501;第75卷(第6期);第644-651页 * |
Trifunctional norrisolide probes for the study of Golgi vesiculation;Gianni Guizzunti,等;《Bioorganic & Medicinal Chemistry Letters》;20061106;第17卷(第2期);第320-325页 * |
光敏剂亚细胞定位研究方法的应用比较;戴维德,等;《中华物理医学与康复杂志》;20050930;第27卷(第09期);第513-516页 * |
应用激光扫描共聚焦显微成像术研究光敏剂亚细胞定位;戴维德,等;《中国激光医学杂志》;20040215;第13卷(第01期);第12-17页 * |
高分辨率荧光显微成像技术在光敏剂亚细胞定位研究中的应用;戴维德,等;《中国激光医学杂志》;20041130;第13卷(第04期);第240-245页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104529893A (zh) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104529893B (zh) | 一类可以作为高尔基体细胞器探针的喹啉染料 | |
Niu et al. | Highly photostable two-photon NIR AIEgens with tunable organelle specificity and deep tissue penetration | |
Sutton et al. | Porphyrin, chlorin, and bacteriochlorin isothiocyanates: useful reagents for the synthesis of photoactive bioconjugates | |
Wang et al. | Cucurbit [8] uril regulated activatable supramolecular photosensitizer for targeted cancer imaging and photodynamic therapy | |
JP5823413B2 (ja) | 新規なポルフィリン誘導体の製造方法、ならびにpdt剤および蛍光プローブとしてのそれらの使用 | |
Kudrevich et al. | Syntheses and photodynamic activities of novel trisulfonated zinc phthalocyanine derivatives | |
CN105566938B (zh) | 一类线粒体靶向的七甲川吲哚花菁染料及制备方法和应用 | |
CN103146220B (zh) | 对称五甲川菁染料及其在分子影像中的应用 | |
Gandioso et al. | High photostability in nonconventional coumarins with far-red/NIR emission through azetidinyl substitution | |
Wei et al. | Dicyanomethylene substituted benzothiazole squaraines: The efficiency of photodynamic therapy in vitro and in vivo | |
JP2004503555A (ja) | 置換金属フタロシアニンならびにその製造法および使用 | |
JP2003534435A5 (zh) | ||
CN103864833B (zh) | 一种轴向端羟基取代硅酞菁及其自组装体 | |
CN102552907B (zh) | 一种非周边取代酞菁锌在制备声敏剂中的应用 | |
Xiang et al. | Synthesis, spectral properties of rhodanine complex merocyanine dyes as well as their effect on K562 leukemia cells | |
Linares et al. | Chlorin derivatives sterically-prevented from self-aggregation with high antitumor activity for photodynamic therapy | |
WO2013131235A1 (zh) | 一类以萘为母体的双光子荧光探针、其制备方法及应用 | |
CN106632063B (zh) | 基于菲并咪唑的化合物i和化合物ii及其制备方法和应用 | |
CN109575061A (zh) | 一种水溶性的抗癌光敏剂及其制备和应用 | |
Fadda et al. | Synthesis of novel cyanine dyes as antitumor agents | |
Kwon et al. | Indolizino [3, 2-c] quinolines as environment-sensitive fluorescent light-up probes for targeted live cell imaging | |
Liao et al. | Tetraphenylporphyrin derivatives possessing piperidine group as potential agents for photodynamic therapy | |
Muthiah et al. | Two complementary routes to 7-substituted chlorins. Partial mimics of chlorophyll b | |
Krzemien et al. | Tuning Photodynamic Properties of BODIPY Dyes, Porphyrins’ Little Sisters | |
Oparina et al. | Metal-and Solvent-free Synthesis of Functionalized Dihydrooxazolo [3, 2-a] indoles by One-Pot Tandem Assembly of 3H-Indoles and Propargylic Alcohols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 |